# US 2003/0225033 A1 · Heat stable colloidal iron oxides coated with reduced carbohydrates and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0225033 A1
- Document ID: US20030225033A1
- Status: Published application
- Kind: A1
- Application number: 10/386,394
- Filed: 2003-03-11
- Published: 2003-12-04
- Earliest claimed: 1999-04-09
- Assignees: AMAG Pharmaceuticals, Inc.
- Inventors: Ernest V. Groman; Kenneth G. Paul; Timothy B. Frigo; Howard Bengele; Jerome M. Lewis
- Web page: https://patentgrep.com/patent/US20030225033A1

## CPC

- A61K 47/61: the organic macromolecular compound being a polysaccharide or a derivative thereof
- A61K 33/26: Iron; Compounds thereof
- A61K 47/6923: {the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb}
- A61K 49/1863: {the organic macromolecular compound being a polysaccharide or derivative thereof, e.g. chitosan, chitin, cellulose, pectin, starch}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 7/06: Antianaemics
- A61P 7/08: Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock (artificial tears A61P27/04)
- A61P 35/00: Antineoplastic agents
- A61P 39/00: General protective or antinoxious agents
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES

## Abstract

Compositions, methods of making the compositions, and methods of using the compositions are provided for an enhanced magnetic resonance imaging agent and a hematinic agent, the agents comprising carboxyalkylated reduced polysaccharides coated ultrasmall superparamagnetic iron oxides. Methods of use of the carboxymethyl reduced dextran as a plasma extender are provided.

## Claims

### Claim 1

An improved method of administering to a mammalian subject a polysaccharide iron oxide complex, wherein the improvement comprises administering a carboxyalkylated reduced polysaccharide iron oxide complex having an extent of carboxyalkylation sufficient to produce decreased edematous response to the carboxyalkylated complex in comparison to an edematous response to an administered polysaccharide that has not been thus carboxyalkylated.

### Claim 2

An improved method of administering to a mammalian subject a polysaccharide wherein the polysaccharide is dextran and wherein the improvement comprises administering a carboxyalkylated reduced dextran having an extent of carboxyalkylation sufficient to produce decreased edematous response to the carboxyalkylated dextran in comparison to an edematous response to an administered dextran that has not been thus carboxyalkylated.

### Claim 3 (depends on 2)

A method according to claim 2, further comprising sterilizing the polysaccharide by autoclaving.

### Claim 4 (depends on 3)

A method according to claim 3, wherein the subject is in need of a plasma extender.

### Claim 5 (depends on 1)

A method according to claim 1, further comprising providing a solution of an iron salt to form a carboxyalkylated reduced dextran iron colloid formulation producing decreased edematous response.

### Claim 6 (depends on 1)

A method according to claim 1, further comprising sterilizing the carboxyalkylated reduced dextran iron oxide complex by autoclaving.

### Claim 7 (depends on 6)

A method according to claim 6, wherein the subject is in need of iron.

### Claim 8 (depends on 7)

A method according to claim 7, wherein the subject in need of iron is selected from the group of: a cancer patient, a gastroenteritis patient, and an erythropoietin recipient.

### Claim 9

An improved method of magnetic resonance imaging (MRI) wherein the improvement comprises administering to a subject an effective dose of a carboxyalkylated reduced polysaccharide iron oxide MRI contrast agent to facilitate magnetic resonance imaging (MRI) of a tissue or organ wherein upon administering the carboxyalkylated reduced polysaccharide MRI contrast agent there is a decreased edematous response in comparison to an administered polysaccharide MRI contrast agent that has not been thus carboxyalkylated.

### Claim 10

An improved method of magnetic resonance imaging (MRI), wherein the improvement comprises administering to a subject successive effective doses of a carboxyalkylated reduced polysaccharide iron oxide MRI contrast agent to facilitate successive magnetic resonance imaging of a tissue or organ wherein upon administering the carboxyalkylated reduced polysaccharide MRI contrast agent there is a decreased edematous response in comparison to an administered polysaccharide MRI contrast agent that has not been thus carboxyalkylated.

### Claim 11 (depends on 9)

A method according to claim 9, wherein the effective dose is about 0.1 to about 4.0 mg of iron per kg of body weight of the subject.

### Claim 12 (depends on 11)

A method according to claim 11, wherein the effective dose is about 0.2 to about 0.6 mg of iron per kg of body weight.

### Claim 13 (depends on 11)

A method according to claim 11, wherein the effective dose is about 0.4 to about 1.0 mg of iron per kg of body weight.

### Claim 14 (depends on 11)

A method according to claim 11, wherein the effective dose is about 1.0 to about 4.0 mg of iron per kg of body weight.

### Claim 15 (depends on 10)

A method according to claim 10, wherein the successive effective doses are administered less than one hour apart.

### Claim 16 (depends on 15)

A method according to claim 15, wherein the successive effective doses are administered less than thirty minutes apart.

### Claim 17

An improved method for obtaining a composition for pharmacological administration from a polysaccharide, wherein the improvement comprises prior to administering:
reducing the polysaccharide; and
carboxyalkylating to an extent sufficient to produce a decreased edematous response in the subject to the administered polysaccharide composition in comparison to an edematous response in the subject to an administered polysaccharide that has not been thus reduced and carboxyalkylated.

### Claim 18 (depends on 17)

A method according to claim 17, wherein the method further comprises:
administering the reduced carboxyalkylated pharmacological polysaccharide composition to a mammalian subject as a plasma extender.

### Claim 19

An improved method for obtaining a composition for pharmacological administration from a dextran, wherein the improvement comprises:
reducing the dextran; and,
carboxyalkylating the dextran to provide an extent of carboxyalkylation sufficient to produce a decreased edematous response to the administered dextran composition in a subject in comparison to an edematous response in a subject to an administered polysaccharide that has not been thus reduced and carboxyalkylated.

### Claim 20 (depends on 17)

A method according to claim 17, further comprising the step of sterilizing the carboxyalkylated reduced dextran composition by autoclaving.

### Claim 21 (depends on 20)

A method according to claim 20, further comprising after sterilizing the step of providing the sterile composition as a single dosage unit.

### Claim 22 (depends on 20)

A method according to claim 20, further comprising the step of administering the composition to a mammal in need of a plasma extender.

### Claim 23 (depends on 20)

A product for use as a plasma extender produced by the improved method of claim 20.
